See the DrugPatentWatch profile for semaglutide

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a medication used to treat type 2 diabetes and, in some countries, for chronic weight management. The drug is marketed under the brand names Ozempic and Rybelsus by Novo Nordisk. As for the patent expiration of semaglutide, it is essential to understand that patents can cover various aspects of a drug, such as the active ingredient, formulation, and manufacturing methods.

According to DrugPatentWatch.com [1], the basic patent for semaglutide (US Patent No. 8,679,029) expired in the United States on March 3, 2020. However, this does not necessarily mean that generic versions of semaglutide will immediately become available. Other patents related to the drug's formulation, form, and methods of use may still be in force, preventing generic competition.

Moreover, Novo Nordisk has filed several patent applications related to semaglutide, some of which have been granted and are still in force. For instance, US Patent No. 10,329,312, which covers a method of treating obesity with semaglutide, is set to expire in 2036 [1].

It is important to note that the patent landscape for semaglutide is complex and subject to change. Interested parties should monitor the situation closely for updates and potential implications on the drug's market exclusivity and the availability of generic alternatives.

Sources:
[1] DrugPatentWatch.com. (n.d.). Semaglutide (Ozempic, Rybelsus) Patents. Retrieved from https://www.drugpatentwatch.com/drugs/semaglutide.html